| Kowa Company, Ltd. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120122906 | NOVEL SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME - Disclosed is a novel compound which has both angiotensin II receptor antagonist activity and PPARγ activating activity, and is useful as a prophylactic and/or therapeutic agent for hypertension, heart diseases, angina pectoris, cerebrovascular disorders, cerebral circulatory disorders, ischemic peripheral circulatory disorders, kidney diseases, arteriosclerosis, inflammatory diseases, type 2 diabetes, diabetic complication, insulin resistant syndrome, syndrome X, metabolic syndrome and hyperinsulinemia. Also disclosed is a pharmaceutical composition which contains the novel compound. Specifically disclosed are: a sulfonamide derivative represented by general formula (I), a salt thereof, or a solvate of the derivative or salt; and a pharmaceutical composition which contains the sulfonamide derivative, a salt thereof, or a solvate of the derivative or salt. (In the formula, R | 05-17-2012 |
| 20120108581 | FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL CONTAINING SAME - The present invention provides a low molecular weight compound having EPO production-promoting action and/or hemoglobin production-promoting action. The present invention relates to a fused piperidine compound represented by the following general formula (1): | 05-03-2012 |
| 20120100624 | OPTICAL REACTION MEASUREMENT DEVICE AND OPTICAL REACTION MEASUREMENT METHOD - Provided is an optical reaction measurement device that measures whether a reaction is occurring between a sample and a reagent, or how a reaction is progressing, on the basis of changes over time of optical properties of a liquid mixture of the sample and the reagent. The preparation time required for tasks such as mixing the sample and the reagent is predetermined, and when a start switch on the measurement device is turned to “on,” a timer starts running, and the time remaining until the preparation time begins is shown to an operator as a countdown. When the count reaches zero, the operator is informed that the preparation time has begun. The amount of time that has passed since the preparation time began is used as time data to accompany measurement data, and optical property data from after the end of the preparation time is used in analysis. | 04-26-2012 |
| 20120046308 | NOVEL ALPHA-PHENOXYBENZENEACETIC ACID DERIVATIVE AND PHARMACEUTICAL PREPARATION COMPRISING SAME - An α-phenoxybenzeneacetic acid derivative represented by general formula (I), which has both an angiotensin II receptor antagonistic activity and a PPARγ activation activity and is useful as a prophylactic and/or therapeutic agent for hypertension, metabolic syndrome or the like, a salt of the derivative, or a solvate of the derivative or the salt; and a pharmaceutical composition containing the derivative, the salt or the solvate. [In the formula, Q represents a group represented by formula (II) or (III) [wherein R | 02-23-2012 |
| 20120028983 | NOVEL COMPOUND HAVING 3-HETEROARYLPYRIMIDIN-4-(3H)-ONE STRUCTURE AND PHARMACEUTICAL PREPARATION CONTAINING SAME - Disclosed is a compound which has both an angiotensin-II receptor antagonistic activity and a PPARγ activation activity and is useful as a prophylactic and/or therapeutic agent for hypertension, heart diseases, angina pectoris, cerebrovascular disorders, cerebral circulatory disorders, ischemic peripheral circulatory disorders, renal diseases, arteriosclerosis, inflammatory diseases, type-2 diabetes, diabetic complications, insulin resistance syndrome, syndrome X, metabolic syndrome and hyperinsulinemia. [In the formula, A represents a 5- to 10-membered heteroaryl group; R | 02-02-2012 |
| 20120015377 | METHOD AND APPARATUS FOR MEASURING BIOGENOUS BIOLOGICALLY ACTIVE SUBSTANCE - Provided is an assay method and an assay device whereby assay time can be largely shortened in the case of detecting a physiologically active substance of biological origin. The aggregation start time of a liquid mixture of an assay sample with LAL is determined. From this aggregation start time, the physiologically active substance is detected or the concentration thereof is measured. The liquid mixture of the assay sample with LAL is stirred with, for example, a magnetic stirrer to form gel particles. Next, the scattered light intensity of laser light scattered by these gel particles is measured. Then, the frequency distribution of the scattered light intensity fluctuation is obtained. Based on the temporal change in the frequency distribution shape, the aggregation start time of the liquid mixture of the assay sample with LAL is determined. | 01-19-2012 |
| 20120004197 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT - Disclosed is a compound which has a low molecular weight and has an activity of enhancing the production of EPO and/or an activity of enhancing the production of hemoglobin. Specifically disclosed is and EPO production enhancer and/or a hemoglobin production enhancer comprising a 1-acyl-4-(substituted oxy, substituted amino, or substituted thio)-1,2,3,4-tetrahydroquinoline derivative, more specifically a tetrahydroquinoline compound represented by general formula (1) [wherein R | 01-05-2012 |
| 20120003745 | METHOD FOR MEASURING PHYSIOLOGICALLY ACTIVE SUBSTANCE OF BIOLOGICAL ORIGIN, PROGRAM FOR IMPLEMENTING THE SAME, AND APPARATUS FOR MEASURING PHYSIOLOGICALLY ACTIVE SUBSTANCE OF BIOLOGICAL ORIGIN - When assessing the start time of the limulus reaction between biogenous biologically active substances and LAL and using the reaction start time to determine the concentration of the biogenous biologically active substances, in order to exclude the influence of progressive changes which occur regardless of the conditions of the limulus reaction, the strength of transmitted light or scattered light in the liquid mixture of the measurement sample and LAL is detected, the variation (delta) in the transmittance or number of gel particles is acquired at set intervals, and the time when the variation (delta) crosses a threshold value is taken as the reaction start time. Furthermore, the time intervals when acquiring the abovementioned delta are not uniform, and either change over time from the start of measurement as defined by a time function, or multiple sequences with differing time intervals are prepared in advance. | 01-05-2012 |
| 20110306623 | NOVEL COMPOUNDS COMPRISING A 3-(5-ALKOXYPYRIMIDIN-2-YL) PYRIMIDIN-4(3H)-ONE STRUCTURE AND DRUGS THAT COMPRISE SAME - Provided are novel compounds that have both angiotensin II receptor-antagonist effects and PPAR-activating effects that are useful as agents for preventing and/or treating hypertension, heart disease, angina, cerebral vascular accident, cerebrovascular disorder, ischemic peripheral circulatory disorder, kidney disease, atherosclerosis, inflammatory disease, type 2 diabetes mellitus, diabetic complication, insulin resistance syndrome, Syndrome X, metabolic syndrome, and hyperinsulinemia. Disclosed are 3-(5-alkoxypyrimidin-2-yl)pyrimidin-4(3H)-one derivatives represented by the General formula (I): [wherein R represents a C | 12-15-2011 |
| 20110288328 | METHOD FOR PREPARING TRANS-ACETIC ACID ESTER - A method for preparing a trans-{4-[(alkylamino)methyl]cyclohexyl}acetic acid, which is useful as a raw material compound for manufacture of medicaments and the like, comprising the step of reducing amide group of a compound represented by the following general formula (6) (R | 11-24-2011 |
| 20110273757 | OPTICAL IMAGE-CAPTURING APPARATUS - Light beams from light sources | 11-10-2011 |
| 20110166351 | METHOD FOR PREPARING 5-[2-(METHYLTHIO)ETHOXY]PYRIMIDINE-2-AMINE - A novel method for preparing 5-[2-(methylthio)ethoxy]pyrimidin-2-amine useful as a regent or raw material for manufacture of medicaments, agricultural chemicals, and industrial products, which comprises alkanoylating the amino group of a 2-amino-4-alkoxypyrimidine, then converting the resultant into a 4-hydroxypyrimidine compound by a treatment with anhydrous aluminum chloride, further etherifying the 4-hydroxypyrimidine compound by a reaction with a 2-haloethyl methyl sulfide in the presence of a base, and removing the alkanoyl group to obtain 5-[2-(methylthio)ethoxy]pyrimidin-2-amine. | 07-07-2011 |
| 20110124036 | METHOD FOR MEASUREMENT OF PHYSIOLOGICALLY ACTIVE SUBSTANCE DERIVED FROM ORGANISM AND MEASUREMENT APPARATUS - Disclosed is a measurement method which can largely reduce the time required for the detection of a physiologically active substance derived from an organism (e.g., an endotoxin, β-D-glucan) or the determination of the concentration of the physiologically active substance by utilizing the reaction between the physiologically active substance and LAL. Also disclosed is a measurement apparatus utilizing the measurement method. An incident light from a light source is focused onto a sample and delivered to the sample to cause the bombardment with coagulin which is a final product of a protease cascade (i.e., a coagulin monomer) and an extremely fine aggregate which is produced by the aggregation of the coagulin monomers (i.e. a coagulin aggregate), thereby generating a scattered light. The scattered light is detected by a light-receiving element. The concentration of the endotoxin can be determined based on the initial rate of increase in the scattered light detected. | 05-26-2011 |
| 20110110903 | CELL FUSION PROMOTER AND UTILIZATION OF THE SAME - It is intended to provide a regeneration promoter for regenerating a tissue with the use of somatic stem cells. It is also intended to provide a cell fusion promoter safely usable in vivo. Namely, it is intended to provide a cell fusion promoter comprising ATP or its metabolite. A cell fusion promoter comprising ATP or its metabolite and a method of producing fused cells in the presence of ATP or its metabolite. A medicinal composition for regenerating or improving the function of a tissue or an organ, which suffers from dysfunction or hypofunction due to injury or denaturation, by using stem cells. This composition comprises ATP or its metabolite and a pharmaceutically acceptable carrier. | 05-12-2011 |
| 20110091902 | METHOD OF ASSAYING PHYSIOLOGICALLY ACTIVE SUBSTANCE OF BIOLOGICAL ORIGIN, KIT FOR ASSAYING PHYSIOLOGICALLY ACTIVE SUBSTANCE OF BIOLOGICAL ORIGIN AND APPARATUS FOR ASSAYING PHYSIOLOGICALLY ACTIVE SUBSTANCE OF BIOLOGICAL ORIGIN - Provided is a technique whereby a physiologically active substance of biological origin such as an endotoxin or β-D-glucan can be more conveniently and accurately detected and the concentration thereof can be determined even in the case of using a sample which contains a substance affecting LAL activity. For example, a sample is brought into contact with a substance ( | 04-21-2011 |
| 20110081351 | ANTIHUMAN BAFF ANTIBODY - An antibody against a peptide having an amino acid sequence AVQGPEETVT QDC (expressed in single letter amino acid code) as represented by SEQ ID: NO. 1 corresponding to the 134- to 146-positions in human BAFF (B cell activating factor belonging to the TNF family) protein which is preferably a monoclonal antibody; a method of producing the above antibody; a medicinal composition containing the antibody; utilization of the antibody; and a method of screening an inhibitory effect or an activating effect on BAFF with the use of the antibody. | 04-07-2011 |
| 20100324091 | Pyrazolone Derivative - A pyrazolone derivative represented by formula (I) below: | 12-23-2010 |
| 20100294722 | BORON ADSORBENT AND BORON REMOVAL METHOD UTILIZING SUGAR AMIDE DERIVATIVE - Disclosed is a boron adsorbent having an excellent adsorbing ability against boron contained in a solution, which is inexpensive and has high general versatility. Also disclosed is a boron removal method which can remove boron efficiently in a simple manner. An amide derivative represented by the general formula (1) is added to a boron-containing water under alkaline conditions to cause the adsorption of boron to the amide derivative. Then, a cation source having two or more valencies is added to the water to cause the aggregation of the amide body. The aggregated amide body is removed from the water. In the general formula (1), m represents 1 or 2; X represents —CH | 11-25-2010 |
| 20100280013 | CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER - [Object] It is to provide a novel LXRβ agonist useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. | 11-04-2010 |
| 20100261933 | METHOD FOR PREPARING CARBOXYLIC ACID COMPOUND - A method for conveniently preparing 2,2-dichloro-12-(4-chlorophenyl)-10-hydroxydodecanoic acid useful as an active ingredient of therapeutic agents for diseases such as diabetes at a high yield, which comprises the step of reacting a compound represented by the following general formula (A): | 10-14-2010 |
| 20100259287 | SEMICONDUCTOR TEST EQUIPMENT - A test head ( | 10-14-2010 |
| 20100249148 | NOVEL PYRIMIDINE COMPOUNDS HAVING BENZYL (HETEROCYCLIC METHYL) AMINE STRUCTURE AND MEDICAMENT COMPRISING THE SAME - A compound represented by the following general formula (I), wherein R | 09-30-2010 |
| 20100222347 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA, COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT - Disclosed is a low-molecular-weight compound having an EPO production-promoting activity and/or a hemoglobin expression-enhancing activity. Specifically disclosed is an EPO production promoter and/or a hemoglobin expression enhancer comprising a 1-acyl-4-(phenoxy, benzyloxy or phenylamino)-1,2,3,4-tetrahydroquinoline derivative, more specifically a tetrahydroquinoline compound represented by the general formula (1); | 09-02-2010 |
| 20100221766 | NUCLEAR TRANSFER PROMOTER FOR Cdc42 PROTEIN AND METHOD OF SCREENING THE SAME - A nuclear transfer promoter for Cdc42 protein comprising an isoprenoid synthesis inhibitor and/or a geranylgeranyl transferase inhibitor such as an HMG-CoA synthase inhibitor, an HMG-CoA reductase inhibitor, an AMPK activator or a farnesyl pyrophosphoric acid synthase preparation; utilization thereof; a method therefor; a blood vessel remedy comprising the nuclear transfer promoter for Cdc42 protein as the active ingredient; and a method of screening a blood vessel remedy which comprises assaying the ability of Cdc42 protein to transfer into nucleus. | 09-02-2010 |
| 20100197698 | 5-PHENYL-3-PYRIDAZINONE DERIVATIVE - To find a compound having a tissue fibrinosis-inhibitory activity and a fibrinolytic activity, and to provide a novel compound that is useful for preventing and/or treating tissue fibrinosis diseases (pulmonary fibrosis, renal fibrosis etc.), diseases caused by pathological blood clots such as ischemic heart diseases (myocardial infarction, angina), intraatrial thrombus, pulmonary embolism, deep venous thrombosis, disseminated intravascular coagulation, ischemic cerebral diseases (cerebral infarction, cerebral bleeding) and arteriosclerosis and the like. To provide a pharmaceutical drug comprising a 5-phenyl-3-pyridazinone derivative represented by the following general formula (I): | 08-05-2010 |
| 20100196948 | METHOD OF SCREENING BAFF SUPPRESSOR OR INHIBITOR - A method of screening a novel BAFF suppressor or inhibitor. More specifically speaking, a method which comprises adding a combination of TPA with ionomycin and/or an anti-CD3 antibody to a cultured human cell to thereby induce the production of BAFF by the cell; a method of screening a substance capable of suppressing the expression or activity of BAFF which comprises adding a test substance to a BAFF-production system prepared by adding a combination of TPA with ionomycin and/or an anti-CD3 antibody to a cultured human cell and measuring the expression amount and/or the activity of BAFF in the BAFF-production system; and a BAFF production inducer for a BAFF-producing cell which contains a combination of TPA with ionomycin and/or an anti-CD3 antibody. | 08-05-2010 |
| 20100184859 | MEDICAMENT HAVING PROMOTING ACTION ON HEPATOCYTE PROLIFERATION - A medicament for promoting proliferation of hepatocytes and liver regeneration, which comprises a polyprenyl compound such as 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid as an active ingredient. | 07-22-2010 |
| 20100173938 | NERVE CELL DEATH INHIBITOR - The present invention provides a medicament exhibiting an excellent nerve cell death inhibitory action. | 07-08-2010 |
| 20100166793 | PROTEASE-RESISTANT MODIFIED SEB AND VACCINE CONTAINING THE SAME - A modified Staphylococcal enterotoxin B (SEB) having resistance to a protease and a reduced toxicity and a vaccine comprising said modified SEB are provided. A modified SEB which has an amino acid sequence as set forth in SEQ ID NO: 1 wherein each of the lysine at 97-position and the lysine at 98-position are substituted with any other amino acid, or a derivative thereof and a vaccine comprising said modified SEB or a derivative thereof. | 07-01-2010 |
| 20100144694 | 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME | 06-10-2010 |
| 20100130985 | Intraocular lens insertion tool - An intraocular lens insertion tool of a novel structure, capable of easily and reliably placing an intraocular lens in a human eye. A placement part ( | 05-27-2010 |
| 20100120914 | MEDICAMENT FOR PROPHYLACTIC AND/OR THERAPEUTIC TREATMENT OF HEPATIC STEATOSIS OR NON-ALCOHOLIC STEATOHEPATITIS - A medicament for prophylactic and/or therapeutic treatment of hepatic steatosis or non-alcoholic steatohepatitis, which comprises a polyprenyl compound (e.g., 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid) as an active ingredient. | 05-13-2010 |
| 20100120844 | TETRAHYDROISOQUINOLINE COMPOUND - The present invention relates a specific tetrahydroisoquinoline compound which is useful as a chemokine receptor type 3 (CCR3) antagonist, and a pharmaceutical composition comprising the same as an active ingredient. The tetrahydroisoquinoline compound of the present invention is useful for the treatment or prevention of a disease in which CCR3 participates. | 05-13-2010 |
| 20100113338 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CORNEAL/CONJUNCTIVAL DISEASE - Disclosed is a novel composition for the treatment of a corneal/conjunctival disease. A prophylactic or therapeutic agent for a corneal/conjunctival disease comprising selenoprotein P as an active ingredient, more specifically a prophylactic or therapeutic agent for a corneal/conjunctival disease such as dry eye, keratoconjunctivitis sicca, superficial punctate keratopathy, corneal erosion or corneal ulcer comprising selenoprotein P as an active ingredient, particularly a prophylactic or therapeutic agent for a corneal/conjuncrtival disease such as dry eye, keratoconjunctivitis sicca, superficial punctate keratopathy, corneal erosion or corneal ulcer accompanied by a corneal/conjunctival epithelial discorder. | 05-06-2010 |
| 20100101996 | BORON-REMOVING AGENT AND BORON REMOVAL METHOD UTILIZING XEROGEL - Disclosed is a boron removal method which can remove boron from boron-containing water satisfactorily by using a small amount of a chemical agent, and which generates small amount of precipitate. Also disclosed is a boron-removing agent which is easy to handle and has excellent boron-adsorption ability. A xerogel of an organic polymeric compound having a cis-type diol structure and a water-soluble salt of an alkaline earth metal are added to a boron-containing water under alkaline conditions. | 04-29-2010 |
| 20100093010 | Inhibitor for the Formation of Gamma-Secretase Complex - It is intended to provide an inhibitor for the formation of a γ-secretase complex which comprises a cholesterol synthesis inhibitor or a protein geranylgeranylation regulator as the active ingredient; and use of a cholesterol synthesis inhibitor or a protein geranylgeranylation regulator for producing the same. It is also intended to provide a method of screening a substance having an effect of inhibiting the formation of an active complex of γ-secretase which comprises assaying the activity of inhibiting cholesterol synthesis or quantifying cholesterol accumulated in lipid rafts in cells. It is also intended to provide a method of screening a cholesterol synthesis inhibitor, a protein geranylgeranylation regulator or an HMG-CoA reductase inhibitor which comprises assaying the effect of inhibiting the formation of an active complex of γ-secretase. Moreover, it is intended to provide a method of screening an effect of a test substance on γ-secretase which comprises measuring the distribution of constituents (niscastrin, APH-1, Pen-2 and so on) required by γ-secretase for the formation of its active complex in cells. | 04-15-2010 |
| 20100075943 | 1-ADAMANTYLAZETIDIN-2-ONE DERIVATIVES AND DRUGS CONTAINING SAME - It is to provide a novel compound useful for preventing and/or treating diseases that involves 11β-hydroxysteroid dehydrogenase 1, particularly diabetes, insulin resistance, diabetes complication, obesity, dyslipidemia, hypertension, fatty liver, or metabolic syndrome. It is an 1-adamantyl azetidin-2-one derivative represented by the following general formula (1) or salt thereof, or their solvate. | 03-25-2010 |
| 20100069433 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR HYPERLIPIDEMIA - The present invention provides a therapeutic agent for hyperlipidemia having an excellent effect of lowering the cholesterol and triglyceride level in blood plasma. | 03-18-2010 |
| 20100068788 | NOVEL MICROORGANISM CAPABLE OF MICROBIALLY DECOMPOSING CHLORO-, METHYLTHIO- AND METHOXY-TRIAZINE AGRICHEMICALS - Disclosed are: a novel microorganism which can decompose a methylthiotriazine compound (particularly, simetryn, dimethametryn, prometryn), a chlorotriazine compound (particularly, simazine, atrazine, propazine) and a methoxytriazine compound (particularly, simeton, atraton, prometon) which have been frequently used as agrichemicals or the like; and a method for decomposing a methylthiotriazine compound, a chlorotriazine compound and/or a methoxytriazine compound by using the microorganism. Specifically disclosed are: a novel bacterium | 03-18-2010 |
| 20100063119 | SUBSTITUTED CARBINOL COMPOUND - There is provided a novel LXRβ agonist useful as a preventative and/or therapeutic agent for arteriosclerosis; arteriosclerosis such as those resulting from diabetes; hyperlipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases caused by inflammatory cytokines, skin diseases such as allergic skin diseases, diabetes or Alzheimer's disease. The agonist is a carbinol derivative represented by the following general formula (1) or salt thereof, or their solvate. | 03-11-2010 |
| 20100048610 | CARBINOL DERIVATIVES HAVING CYCLIC LINKER - [Object] To provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. | 02-25-2010 |
| 20100035927 | MEDICAMENT FOR PROPHYLACTIC AND/OR THERAPEUTIC TREATMENT OF ALZHEIMER-TYPE DEMENTIA - A medicament for prophylactic and/or therapeutic treatment of Alzheimer-type dementia, which comprises donepezil hydrochloride and valproic acid or a salt thereof in combination. | 02-11-2010 |
| 20100022572 | NOVEL SPIRO COMPOUND AND MEDICINE COMPRISING THE SAME - It is to provide a novel compound useful for preventing and/or treating diabetes, insulin resistance, diabetes complication, obesity, dyslipidemia, hypertension, fatty liver, or metabolic syndrome. | 01-28-2010 |
| 20100016327 | QUINOLINE COMPOUNDS - [Object] To provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. | 01-21-2010 |
| 20100015688 | NOVEL MICROORGANISM CAPABLE OF DEGRADING DIPHENYLARSINIC ACID - Disclosed are: a microorganism capable of degrading diphenylarsinic acid; a method for degrading diphenylarsinic acid by using the microorganism; a method for clean-up of a contaminated soil by using the microorganism; an agent for degrading diphenylarsinic acid, which comprises the microorganism; and a cleaning agent for a contaminated soil or groundwater, which comprises the microorganism. Specifically disclosed are: a microorganism belonging to the genus | 01-21-2010 |
| 20100003312 | EXTERNAL SKIN PATCH - An object of the invention is to provide a hydrous external skin patch, which has adherence sufficient for adhering to an affected area for several times without using an auxiliary tape or the like and is excellent in utility so that the patch can be easily peeled off even if the paste adheres to itself before application to the affected area. | 01-07-2010 |
| 20090292294 | INTRAOCULAR LENS INSERTION TOOL - An insertion tool of an intraocular lens of novel structure in which the intraocular lens can be deformed into smaller one while rotation of the intraocular lens in an insertion tube is effectively prevented. Upper and lower flat planes ( | 11-26-2009 |
| 20090286780 | 2-OXOCHROMENE DERIVATIVES - To provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. | 11-19-2009 |
| 20090264529 | ACTIVATORS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS - Activators of peroxisome proliferator-activated receptors comprising a polyprenyl compound, preferably (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid, as an active ingredient, and medicaments for preventive and/or therapeutic treatment of hyperlipidemia, non-insulin dependent diabetes mellitus or the like comprising a polyprenyl compound as an active ingredient. | 10-22-2009 |
| 20090247587 | 1,3-DIHYDROISOBENZOFURAN DERIVATIVES - The object is to provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. The solving means is a 1,3-dihydroisobenzofuran derivative represented by the following general formula (1) or salt thereof, or their solvate. | 10-01-2009 |
| 20090215703 | PAR-2 Agonist - The present invention relates to a pharmaceutical composition for preventing/treating conditions associated with PAR-2. The present invention also relates to a method for preventing/treating the condition using the pharmaceutical composition and use for manufacturing the pharmaceutical composition. The pharmaceutical composition comprises a compound represented by the following general formula (1), salt or solvate thereof and a pharmaceutically acceptable carrier: Ar—CO-AA | 08-27-2009 |
| 20090082861 | INTRAOCULAR LENS - A one-piece intraocular lens realizing adhesion of the intraocular lens to the inner surface of a capsule more advantageously by viscosity imparted to the intraocular lens, and being deployed more positively after it is inserted into the capsule and secured therein while being positioned at a specified location. The intraocular lens has an optical portion ( | 03-26-2009 |
| 20090082352 | NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE AND MEDICAMENT COMPRISING THE SAME - A compound represented by the following general formula (I), wherein R | 03-26-2009 |
| 20090062306 | NOVEL PYRIMIDINE COMPOUNDS HAVING BENZYL (HETEROCYCLIC METHYL) AMINE STRUCTURE AND MEDICAMENT COMPRISING THE SAME - A compound represented by the following general formula (I), wherein R | 03-05-2009 |
| 20090054474 | Novel pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same - A compound represented by the following general formula (I) or a salt thereof, or a solvate thereof: | 02-26-2009 |
| 20090050574 | AGENT FOR REMOVING BORON AND METHOD FOR REMOVING BORON - Boron is removed from an aqueous boron solution by contacting with the aqueous boron solution with a water-soluble cationic polyelectrolyte, and at least one of polyvinyl alcohol and anionic-modified polyvinyl alcohol under an alkaline condition, and then removing the generated coagulation. | 02-26-2009 |
| 20090043384 | INTRAOCULAR LENS - An intraocular lens of novel structure exhibiting an excellent focus adjusting power. A hollow capsule structure is filled with a transparent liquid-like or gel-like filler ( | 02-12-2009 |
| 20090030514 | INTRAOCULAR LENS - An intraocularlens of novel structure by which the outer circumferential part of an optical portion can be pressed stably against a posterior capsule under worn state and crisis of secondary cataract can be suppressed more advantageously. A pair of coupling portions ( | 01-29-2009 |
| 20090012263 | Process for Production of (1,3-Disubstituted Indolyl)-Urea Derivatives, Intermediates Therefor, and Process for Production of the Intermediates - A process for the production of (1,3-disubstituted indolyl) urea derivatives represented by the general formula (1), characterized by reacting a 1-substituted-aminoindole derivative with a phenyl halocarbonate to form a carbamate derivative, subjecting the carbamate derivative to Mannich reaction with a secondary amine and formaldehyde to form a 3-aminomethylindole derivative represented by the general formula (6), and then reacting the derivative (6) with a peptide derivative; indole derivatives represented by the general formula (6) which are intermediates for the above process; and a process for the production of the indole derivatives. | 01-08-2009 |
| 20090012006 | Par-2 Antagonists - Compounds represented by the general formula (1) or salts thereof or solvates of both; PAR-2 antagonists containing the compounds; and preventive or therapeutic agents for PAR-2 related diseases containing the antagonists as the active ingredient: (1) wherein R | 01-08-2009 |
| 20080305502 | Method of Screening Baff Suppressor or Inhibitor - A method of screening a novel BAFF suppressor or inhibitor. More specifically speaking, a method which comprises adding a combination of TPA with ionomycin and/or an anti-CD3 antibody to a cultured human cell to thereby induce the production of BAFF by the cell; a method of screening a substance capable of suppressing the expression or activity of BAFF which comprises adding a test substance to a BAFF-production system prepared by adding a combination of TPA with ionomycin and/or an anti-CD3 antibody to a cultured human cell and measuring the expression amount and/or the activity of BAFF in the BAFF-production system; and a BAFF production inducer for a BAFF-producing cell which contains a combination of TPA with ionomycin and/or an anti-CD3 antibody. | 12-11-2008 |
| 20080287391 | Cell Fusion Promoter and Utilization of the Same - It is intended to provide a regeneration promoter for regenerating a tissue with the use of somatic stem cells. It is also intended to provide a cell fusion promoter safely usable in vivo. Namely, it is intended to provide a cell fusion promoter comprising ATP or its metabolite. A cell fusion promoter comprising ATP or its metabolite and a method of producing fused cells in the presence of ATP or its metabolite. A medicinal composition for regenerating or improving the function of a tissue or an organ, which suffers from dysfunction or hypofunction due to injury or denaturation, by using stem cells. This composition comprises ATP or its metabolite and a pharmaceutically acceptable carrier. | 11-20-2008 |
| 20080275081 | Novel thrombomodulin expression promoters - It is intended to provide a novel pharmaceutical effect of HMG-COA reductase inhibitors, in particular, (+)-(3R, 5S, 6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-di hydroxy-6-heptenoic acid or its salt. Namely, TM expression promoters, more specifically speaking, antithrombotic drugs, preventive/remedies for sepsis, antiplatelet drugs and anticoagulants comprising as the active ingredient an HMG-COA reductase inhibitor, in particular, (+)-(3R, 5S, 6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoic acid or its salt. | 11-06-2008 |
| 20080227849 | Orally Disintegrable Solid Preparation Comprising Povidone-Iodine - An orally disintegratable solid preparation comprising povidone-iodine as an active ingredient, which is obtained by direct powder compression of a mixture containing a granular sugar alcohol and povidone-iodine, wherein the mixture does not contain a basic ingredient and is not subjected to wet granulation. High quality solid preparation as an orally disintegratable preparation comprising povidone-iodine, which have a constant content of povidone-iodine per a single unit solid preparation and maintain stability of iodine, are provided. | 09-18-2008 |
